Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally stabilizing and corporate balance sheets bulging with record-breaking liquidity, the stage is set for a massive wave of
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.
Biotech Stock Gets Booted in Latest Fund Update Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer Nuvalent reports durable neladalkib responses in pretreated and TKI-naïve ALK-positive NSCLC, with strong rates in the ALKOVE-1 trial.
